Figures
In Fig 5, the beta-actin is incorrect in panel B. Please see the correct Fig 5 here.
A. Dose-dependently, phosphorylation of PI3K and AKT and the expression of survivin and XIAP, anti-apoptotic factors, were decreased while the expression of BAD, a pro-apoptotic factor, was increased 48 hours after treatment with iMDK. Shown is immunoblot performed as described in Methods. B. Time-dependently, phosphorylation of PI3K and AKT and the expression of survivin and XIAP were decreased while the expression of BAD was increased by treatment with iMDK at a concentration of 50 nM. Immunoblot was performed as described in Methods.
Reference
Citation: Hao H, Maeda Y, Fukazawa T, Yamatsuji T, Takaoka M, Bao X-H, et al. (2024) Correction: Inhibition of the Growth Factor MDK/Midkine by a Novel Small Molecule Compound to Treat Non-Small Cell Lung Cancer. PLoS ONE 19(7): e0307052. https://doi.org/10.1371/journal.pone.0307052
Published: July 9, 2024
Copyright: © 2024 Hao et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.